Ibrutinib in Relapsed/refractory Patients with Waldenström Macroglobulinemia: a Real-Life, Retrospective Study on Behalf of the “RTL” (regional Tuscan Lymphoma Network)

Ibrutinib represents the first approved treatment for patients with Waldenström macroglobulinemia (WM). There are very few published experiences outside of a clinical trial. In this study, we investigated treatment response, survival, and safety in a real life setting. We retrospectively analyzed 49 consecutive R/R WM patients, managed in 8 Tuscan onco-hematological centers, that received ibrutinib after its approval, at a maximum dose of 420 mg once per day, until disease progression or unacceptable toxicity. Median age was 65 years (range 32–86), and the median number of previous regimens was 2 (range 1–5). Overall and major response rate were 91.8